Home Latest Articles
Latest Articles
  • Li JIANG, Mei XIE, Xudong QIAO
    World Clinical Drug. 2022, 43(7): 863-867.
    Objective

    To investigate the efficacy of tenofovir alafenamide combined with mycophenolate mofetil in the treatment of hepatitis B-related immunoglobulin (Ig) A nephropathy.

    Methods

    A total of 82 patients with hepatitis B-related IgA nephropathy admitted to our hospital from February 2016 to February 2020 were included for retrospective analysis of their medical records, and 41 patients treated with tenofovir alafenamide were set as controls group, 41 patients treated with tenofovir alafenamide combined with mycophenolate mofetil were set as the study group. The clinical efficacy between the two groups were compared. The liver and kidney function and serum marker levels of hepatitis B virus (HBV) in the two groups before and after treatment were compared.

    Results

    The total effective rate in the study group was 95.12%, which was significantly higher than 78.05% in the control group (P<0.05). After treatment, the 24-hour urinary protein quantification (24-UCFP) and alanine aminotransferase (ALT) in the two groups were significantly lower than those before treatment (P<0.05), and albumin (Alb) was significantly higher than that before treatment (P<0.05). After treatment, 24-UCFP and ALT in the study group were significantly lower than those in the control group (P<0.05), and Alb was significantly higher than that in the control group (P<0.05). After treatment, the negative rate of HBV-DNA positive in the study group was significantly higher than that in the control group (P<0.05).

    Conclusion

    Tenofovir alafenamide combined with mycophenolate mofetil in the treatment of hepatitis B-related IgA nephropathy has a definite clinical effect, and has high application value for the improvement of liver and kidney function and the control of HBV.

  • Xiaoxia WEI, Shupeng DUAN, Bin ZHU
    World Clinical Drug. 2022, 43(7): 868-872.
    Objective

    To investigate the impact of Shenqi Gankang tablets on clinical efficacy and immune function in the treatment of chronic hepatitis B (CHB).

    Methods

    A total of 182 patients with CHB from Department of Infectious Diseases, the First Affiliated Hospital of Xinxiang Medical University between January 2017 to December 2019 were collected. All patients were randomly divided into control group (n=91) and observation group (n=91). The control group was given entecavir maleate tablets, 0.5 mg/time, one time/d and the observation group was additional given Shenqi Gankang tablets, 2.1 g/time, 3 times/d on the basis of the control group. Two groups were treated for 6 months. The differences of clinical efficacy, liver function index (AST、ALT), liver fibrosis index (LN、HA、PCⅢ, Ⅳ-C), T lymphocyte subsets index (CD4+, CD8+, CD4+/CD8+), cytokine levels index (IFN-γ, IL-2, IL-4, IL-10) and incidence of adverse reactions between two groups were compared after treatment.

    Results

    The total effective rates in the observation group was significantly higher than control group (P=0.014). After treatment, the ALT, AST, LN, HA, PCⅢ, Ⅳ-C, CD8+ cells, IL-4, IL-10 of two groups were significantly reduced, while CD4+ cells, CD4+/CD8+ ratio value, IFN-γ, IL-2 were significantly increased, with statistically significant differences between two groups before and after treatment (P<0.05). After treatment, the ALT, AST, LN, HA, PCⅢ, Ⅳ-C, CD8+ cells, IL-4, IL-10 of the observation group were significantly lower than that of the control group, while CD4+ cells, CD4+/CD8+ ratio value, IFN-γ, IL-2 were higher than that of the control group, with statistically significant differences (P<0.05). The incidence of adverse reactions in control and observation group was 13.19% and 12.08%, respectively. There was no significant difference between the two groups (P=0.823).

    Conclusion

    Shenqi Gankang tablet is safe and effective in the treatment of CHB, and it could significantly improve liver function and alleviate the degree of liver fibrosis. Shenqi Gankang tablet can also promote Th1 cell immune response and enhance immune function.

  • Xin XIE, Haiyan SHI, Juan HAO, Jibo LIU, Jian WU
    World Clinical Drug. 2022, 43(7): 873-877.
    Objective

    To observe the effects of Yiqi Yangyin recipe on serum bilirubin metabolism and insulin resistance (IR) in patients with type 2 diabetes mellitus (T2DM) combined with atherosclerosis (AS).

    Methods

    A total of 64 T2DM patients combined with AS admitted to the outpatient and inpatient Department of Endocrinology, Shanghai University of Traditional Chinese and Western Medicine, Shanghai Traditional Chinese Medicine (TCM)-Integrated Hospital from October 2018 to September 2019 were selected and randomly divided into observation group and control group, with 32 cases in each group. The control group was treated with routine treatment, and the observation group was treated with Yiqi Yangyin recipe on the basis of routine treatment. The course of treatment was 8 weeks. The total curative effect of TCM clinical syndromes, serum bilirubin level, homeostasis model assessment of insulin resistance (HOMA-IR) and fasting insulin (FINS) were observed.

    Results

    After treatment, the levels of serum total bilirubin and serum conjugated bilirubin in the observation group were higher than those before treatment and the differences were statistically significant (P<0.001), and the improvement in the observation group was better than that in the control group, the difference was statistically significant (P<0.001). There was singnificant difference in the total curative effect of TCM clinical syndromes between the two groups (P<0.05). HOMA-IR and FINS in the observation group were significantly lower than those before treatment (P<0.001), and difference between the two groups was statistically significant (P<0.001).

    Conclusion

    Yiqi Yangyin recipe can significantly improve the metabolism of serum bilirubin and FINS and IR levels in patients with T2DM combined with AS, reflecting the basic pathogenesis of "consumptive thirst" and "deficiency of both Qi and Yin" in Yiqi Yangyin recipe, and embodying the principle of "treating diseases must be based on the principle" and providing a research direction for the prevention and treatment of T2DM combined with AS with TCM.

  • Changyuan LIU, Shuping ZHENG, xin CHEN
    World Clinical Drug. 2022, 43(7): 878-884.
    Objective

    To investigate the association between triglyceride-glucose (TyG) index and left ventricular hypertrophy (LVH) and albuminuria in patients with hypertension.

    Methods

    The study participants were recruited from a residential area in the suburb of one district in Shanghai. General information and diseases history of patients with hypertension were collected by questionnaire survey. Brachial artery blood pressure was measured by Omron monitor (HEM-7124). Fasting blood was collected for biochemical including triglyceride and fasting blood glucose. Urinary protein and LVH determined by electrocardiogram Cornell product were used as indicators of target organ damage in hypertensive.

    Results

    The mean age of 5 190 subjects had was (66.41±7.77) years, including 2 423 (46.7%) men, and the mean TyG index was (8.67±0.57). The TyG index of men was lower than that of women [(8.64±0.58) vs (8.69±0.55), P=0.001]. The patients were grouped by the quartile of TyG index (<8.27, 8.27≤TyG index<8.62, 8.62≤TyG index<8.98, ≥8.98), the prevalence of LVH were 4.1%, 3.4%, 4.5% and 6.2%, trend P=0.005, and the prevalence of albuminuria were 1.9%, 2.1%, 2.3% and 3.0%, trend P=0.041, respectively. Multivariate logistic regression analysis showed that the hypertensive patients in the highest quartile group had a 138% increased risk of developing LVH compared with those with the lowest quartile of TyG index group after adjustment for associated risk factors (odds ratio=2.38, 95% confidence interval: 1.45 - 6.83, P<0.001), but there was no significant association between the prevalence of albuminuria and TyG index (P≥0.22).

    Conclusions

    TyG index was associated with LVH and albuminuria, and was an influence factor for LVH in hypertension.

  • Guili CHANG, Changyuan LIU, Mingchun LI, Zhe HU, Jing CHEN, Qunan CAO, Xin CHEN, Shaoli CHU
    World Clinical Drug. 2022, 43(7): 885-890.
    Objective

    To analyze the related factors of proteinuria in patients with primary aldosteronism (PA), and to explore the pathogenic factors and possible mechanism of renal damage caused by PA.

    Methods

    Patients hospitalized in the department of hypertension, Northern Area of Ruijin Hospital and screened as suspected PA were selected from January 2013 to December 2019. The patients were divided into PA group (post salt aldosterone>100 pg/ml) and essential hypertension (EHT) group (post salt aldosterone<60 pg/ml). The baseline characteristic, blood biochemistry, related hormones and 24-hour urinary protein were collected. Proteinuria was defined as 24-hour urinary protein quantity>150 mg.

    Results

    A total of 374 patients were selected, including 142 patients in PA group, accounting for 37.98%. The detection rates of proteinuria and the urine protein quantity in PA group were higher than those in EHT group (P<0.05). Logistic regression analysis was used to correct the relevant risk factors. The risk of proteinuria in PA group was 2.23 times higher than that in EHT group (P=0.016). Furthermore, multiple linear regression was used to analyze the influencing factors of urinary proteinin PA patients. For every 1 pg/dl increase of autonomic aldosterone secretion, urinary proteinin increased by 1.32 mg/24 hours. Autonomously secreted aldosterone, blood glucose, course of disease and male are the risk factors of urinary protein.

    Conclusion

    The incidence of proteinuria was higher in PA patients than in EHT patients. Autonomously secreted aldosterone, blood glucose, course of disease and male are the influencing factors of proteinuria in PA patients, especially autonomously secreted aldosterone may be a variable and specific pathogenic factor of renal damage caused by PA.

  • Kexin SONG, Yan ZHANG, Xuejian LI, Qingli JIANG
    World Clinical Drug. 2022, 43(7): 891-894.
  • Pinggui ZHANG, Yuting SHEN, Yirong BAO
    World Clinical Drug. 2022, 43(7): 895-899.
    Objective

    To explore the clinical efficacy of two groups of different methotrexate (MTX) treatment schemes patients with ectopic pregnancy, and provide theoretical basis for clinical treatment.

    Methods

    A total of 548 patients with ectopic pregnancy treated with MTX in our hospital from June 30, 2018 to June 30, 2021 were selected as the research objects. According to different MTX treatment schemes, they were divided into group A (single-dose regimen group, n=495) and group B (two-dose regimen group, n=53). The clinical data characteristics and treatment effects of the two groups were compared and analyzed.

    Results

    The median of hospitalization time in group A was 10.00 (7.50, 14.50) days, and that was 16.75 (13.87, 20.00) days in group B, and there was significant difference in the average hospitalization time between the two groups (Z=-5.774, P<0.001). The median hospitalization cost in group A was 3945.00 (2880.30, 5166.50) yuan, and that was 4889.60 (4106.30,6697.68) in group B, and there was a statistical difference in the overall distribution of hospitalization cost between the two groups (Z=-3.714, P<0.001). The median time of serum β-HCG turning negative was 20.00 (14.00, 26.00) days in group A and 23.50 (18.00, 30.00) days in group B, and there was a statistical difference in the time distribution of serum β-HCG turning negative between the two groups (Z=-2.816, P=0.005). There were no significant differences between the two groups in the success rate of treatment, the rate of repeated single administration, the disappearance time of mass and the incidence of adverse reactions (P>0.05).

    Conclusion

    Both MTX treatment regimens are safe and effective in the conservative treatment of ectopic pregnancy. The single dose regimen more cost-effective in terms of hospitalization time and hospitalization expenses.

  • Jian MING, Wei CHEN, Min JIN, Guanqi HONG, Jingya WU, Shanlian HU
    World Clinical Drug. 2022, 43(7): 900-910.
    Objective

    To evaluate the comparative efficacy and economic value of polysaccharide iron complex (PIC) and other oral iron supplements (ferrous sulfate, ferrous succinate, iron dextran) in treating iron deficiency anemia (IDA) patients.

    Methods

    Published clinical studies of PIC and other oral iron supplements in the treatment of chronic kidney disease (CKD) complicated with IDA, IDA patients during pregnancy, and children with IDA were systematically searched. Meta-analysis was performed to analyze the clinical efficacy. A decision tree model was constructed to perform cost analysis.

    Results

    A total of 169 studies were identified, and 22 studies were finally included. For CKD patients with IDA, PIC had higher effective rate (94% vs 87% vs 85%) and lower adverse event (AE) rate (19% vs 84% vs 88%) compared to ferrous sulfate and ferrous succinate. The average total treatment cost per patient was decreased by ¥535 (14%) and ¥1 839 (36%) respectively in a 12-month treatment course. For pregnant IDA patients, PIC had higher effective rate (95% vs 77% vs 80% vs 77%) and lower AE rate (6% vs 38% vs 9% vs 21%) compared to ferrous sulfate, ferrous succinate and iron dextran. The average total treatment cost was decreased by ¥270 (17%), ¥654 (33%) and 3 024 (70%) respectively in a 5-month treatment course. For children with IDA, PIC had higher effective rate (91% vs 84%) and lower AE rate (8% vs 51%) compared to ferrous sulfate and exhibited a cost saving of ¥119 (14%) in a 3-month treatment course. Results of sensitivity analysis supported the robustness of the findings.

    Conclusion

    For all three types of IDA populations, PIC demonstrated better clinical efficacy and produced cost savings in comparison to other oral iron supplements.

  • Yuyan FU, Xiaoxiao QIN, Wendi CHENG, Haiyin WANG
    World Clinical Drug. 2022, 43(7): 911-916.
    Objective

    To comprehensively analyze and evaluate the multi-dimensional value of acetyl-levo-carnitine, epalrestat and mecobalamin in the treatment of diabetic peripheral neuropathy (DPN), to provide a basis for clinical rational drug use.

    Methods

    The efficacy, safety, cost-effectiveness and innovation of acetyl-levo-carnitine, epalrestat and mecobalamin were comprehensively compared by literature review.

    Results

    In terms of efficacy, acetyl-levo-carnitine was significantly better than mecobalamin in the median sensory nerve conduction velocity, and it was better than that of mecobalamin in the improvement of pain symptoms. Other efficacy indicators of acetyl-levo-carnitine were similar to mecobalamin and epalrestat. In terms of safety, the incidence of adverse reactions or serious adverse events of acetyl-levo-carnitine, epalrestat and mecobalamin was similar, and all of them were mild adverse reactions. In terms of cost-effectiveness, acetyl-levo-carnitine is more cost-effective than epalrestat and mecobalamin. In terms of innovation, acetyl-levo-carnitine has the dual effects of improving cellular energy metabolism and analgesia in nerve cells.

    Conclusion

    acetyl-levo-carnitine, epalrestat and mecobalamin have little difference in efficacy and safety. In terms of economy and innovation, acetyl-levo-carnitine has higher value.

  • Yao MENG, Xiaoling WANG, Yujie QI
    World Clinical Drug. 2022, 43(7): 917-921.
News